Takis has recently developed new assays to test in mouse models and in human PBMCs the activity of immune checkpoint inhibitors.

The assays allowed the screeening and the identification of candidates for clinical development.

 panel for Immune Oncology

Moreover, the possibility to follow 13 parameters at same time, allows to monitor how peripheral cell population changes over time in cancer patients treated with Immune Checkpoint modulators.


For more info, This email address is being protected from spambots. You need JavaScript enabled to view it.!